WO2017129088A1 - 一种含有喹啉衍生物或其盐的药物组合物的制备方法 - Google Patents

一种含有喹啉衍生物或其盐的药物组合物的制备方法 Download PDF

Info

Publication number
WO2017129088A1
WO2017129088A1 PCT/CN2017/072156 CN2017072156W WO2017129088A1 WO 2017129088 A1 WO2017129088 A1 WO 2017129088A1 CN 2017072156 W CN2017072156 W CN 2017072156W WO 2017129088 A1 WO2017129088 A1 WO 2017129088A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
wetting agent
producing
weight
Prior art date
Application number
PCT/CN2017/072156
Other languages
English (en)
French (fr)
Inventor
卢韵
张新华
王晨阳
Original Assignee
江苏恒瑞医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16/071,572 priority Critical patent/US10722469B2/en
Priority to SI201730345T priority patent/SI3378479T1/sl
Application filed by 江苏恒瑞医药股份有限公司 filed Critical 江苏恒瑞医药股份有限公司
Priority to ES17743703T priority patent/ES2811031T3/es
Priority to CA3008701A priority patent/CA3008701A1/en
Priority to EP17743703.5A priority patent/EP3378479B1/en
Priority to CN201780000924.3A priority patent/CN107405345A/zh
Priority to RS20200902A priority patent/RS60747B1/sr
Priority to JP2018534780A priority patent/JP6937308B2/ja
Priority to AU2017211737A priority patent/AU2017211737B2/en
Priority to PL17743703T priority patent/PL3378479T3/pl
Priority to RU2018128416A priority patent/RU2735807C2/ru
Priority to BR112018014544-0A priority patent/BR112018014544A2/zh
Priority to MX2018008862A priority patent/MX2018008862A/es
Priority to DK17743703.5T priority patent/DK3378479T3/da
Priority to KR1020187022626A priority patent/KR20180103090A/ko
Priority to LTEP17743703.5T priority patent/LT3378479T/lt
Publication of WO2017129088A1 publication Critical patent/WO2017129088A1/zh
Priority to HK18103053.8A priority patent/HK1243357A1/zh
Priority to HRP20201155TT priority patent/HRP20201155T1/hr
Priority to CY20201100686T priority patent/CY1123149T1/el

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention belongs to the field of pharmaceutical preparations, and in particular to a preparation method of a pharmaceutical composition, the composition containing the chemical name (R, E)-N-(4-(3-chloro-4-(pyridin-2-yl) Active drug of methoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)-acrylamide or
  • the pharmacologically acceptable salt and at least one pharmaceutically acceptable excipient are subjected to wet granulation using a wetting agent containing at least one organic solvent during the preparation of the pharmaceutical composition of the present invention.
  • the pharmaceutical composition prepared by the method of the present invention has the characteristics of uniform particle distribution during preparation, rapid and uniform dissolution of the composition. .
  • CN102471312B discloses a small molecule compound (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxy
  • R,E small molecule compound
  • EGFR epidermal growth factor receptor
  • ERBB2 human epidermal factor receptor 2
  • CN102933574B discloses maleate forms of the compounds of formula I which are advantageous in terms of solubility and bioavailability and pharmacokinetics relative to other salts and compounds of formula I.
  • CN103974949B discloses Form I crystals of the compound dimaleate salt of the formula I.
  • the crystal form has good crystal form stability and chemical stability and can be used for the preparation of a medicament for treating diseases associated with the EGFR receptor tyrosine kinase or the HER-2 receptor tyrosine kinase.
  • the invention provides a preparation method of a pharmaceutical composition, comprising:
  • the active drug (R,E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6 -yl)-3-(1-methylpyrrolidin-2-yl)-acrylamide or a pharmacologically acceptable salt thereof is mixed with a wetting agent and granulated.
  • the pharmacologically acceptable salt may be a hydrochloride, a maleate, a hydrobromide, a p-toluenesulfonate, a methanesulfonate, a sulfate or an ethanesulfonate, preferably a maleate, more Preference is given to dimaleate.
  • the content of the active ingredient may range from 5% to 70%, preferably from 10% to 50%, more preferably from 20 to 40%, based on the total weight of the composition, based on the total weight of the composition.
  • the wetting agent can be finally removed by a drying process during the granulation process.
  • the wetting agent may comprise at least one organic solvent, and may further comprise water, wherein the organic solvent may be a low toxicity organic solvent, preferably ethanol, acetone or the like, more preferably ethanol.
  • the content of the organic solvent may be 20 to 100%, preferably 50 to 95%, more preferably 50 to 80%, based on the total weight of the wetting agent.
  • the present invention provides a method for preparing a pharmaceutical composition, which further comprises drying the prepared granules, and then tableting or filling into capsules to obtain an oral solid preparation for clinical administration.
  • the pharmaceutical composition may contain one or more pharmaceutically acceptable excipients such as a filler, a disintegrant, a binder, a lubricant and the like.
  • the filler may be one or more of microcrystalline cellulose, calcium hydrogen phosphate, mannitol, pregelatinized starch, lactose, and the like.
  • the filler content is from about 5 to 80%, based on the total weight of the composition.
  • the binder may be one or more of hypromellose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, methylcellulose, etc., based on the total weight of the composition.
  • the binder content is from about 0.5% to about 15%.
  • the disintegrant may be one or more of low-substituted hydroxypropylcellulose, croscarmellose sodium, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, of which crosslinked polyethylene is preferred.
  • the pyrrolidone, the disintegrant is contained in an amount of 2 to 20%, preferably 4 to 15%, more preferably 6 to 10% based on the total mass of the composition.
  • the lubricant may be one or more of talc, magnesium stearate, zinc stearate, glyceryl behenate, sodium lauryl sulfate, hydrogenated vegetable oil, colloidal silica, and the like.
  • the lubricant is present in an amount of from about 0.5% to about 5%, based on the total weight of the composition.
  • one or more of the excipients may be mixed with a wetting agent and an active ingredient to be granulated. Then drying; or adding one or more excipients after drying the granules prepared by mixing only the active ingredient with the wetting agent; it is also possible to mix a part of the excipient with the active ingredient and the wetting agent and A part is added after granulation and drying.
  • the filler, the disintegrant and the binder are mixed together with the active ingredient and the wetting agent, The granules are then dried and a lubricant is added.
  • the invention also provides a preparation method of a pharmaceutical composition, comprising:
  • a binder selected from one or more of polyvinylpyrrolidone, hydroxypropylmethylcellulose and hydroxypropylcellulose;
  • a lubricant selected from one or more of magnesium stearate and talc.
  • the content percentage of each component is based on the total weight of the pharmaceutical composition.
  • the particle size distribution prepared by wet granulation in the wet granulation is more desirable than the pure water, and the wetting agent containing the low toxicity organic solvent such as ethanol is prepared into an oral solid preparation. After that, the dissolution of the active drug is more rapid and complete and uniform, which is more conducive to the drug's efficacy.
  • the pharmaceutical composition prepared by the preparation method provided by the present invention has rapid dissolution and remarkable effect, and can be used for the treatment of cancer such as gastric cancer, lung cancer or breast cancer.
  • Fig. 1 shows the particle size fractions of Examples 1 to 5 and Comparative Example 1.
  • Figure 2 shows the dissolution profile of a plurality of samples of Comparative Example 1 in a 0.1 mol/L hydrochloric acid solution.
  • Figure 3 shows the dissolution profile of the multiple samples of Example 1 in a 0.1 mol/L hydrochloric acid solution.
  • Figure 4 shows the dissolution profile of a plurality of samples of Example 2 in a 0.1 mol/L hydrochloric acid solution.
  • Figure 5 shows the dissolution profile of the multiple samples of Example 3 in a 0.1 mol/L hydrochloric acid solution.
  • Figure 6 shows the dissolution profile of a plurality of samples of Example 4 in a 0.1 mol/L hydrochloric acid solution.
  • Figure 7 shows the dissolution profile of a plurality of samples of Example 5 in a 0.1 mol/L hydrochloric acid solution.
  • Figure 8 shows the dissolution profiles of the tablets of Examples 6 to 11 in a 0.1 mol/L hydrochloric acid solution.
  • granules For the granules, add a prescribed amount of magnesium stearate and mix using a rotary total mixer. The obtained total mixed granules were dispensed into 100 g for sieving, and the remaining granules were tableted and coated to prepare tablets.
  • Example 1 100 g of the divided granules obtained in Examples 1 to 5 and Comparative Example 1 were sieved by a 50-mesh, 100-mesh sieve. Compared with Example 1, purified water was used as the wetting agent, and the prepared granules, large particles and fine powder were more, and the particle size distribution was not satisfactory. The particle size distribution of the prepared particles using the wetting agent containing ethanol was used in Examples 1 to 5. More uniform, less large particles and fine powder.
  • the tablets of Examples 1 to 5 and Comparative Example 1 were subjected to dissolution measurement according to the second method (paddle method) of the dissolution test of the Appendix 2 of the Chinese Pharmacopoeia.
  • 900 ml of a 0.1 mol/L hydrochloric acid solution was used as a dissolution medium, and a dissolution test was performed at 37 ⁇ 0.5 ° C at a paddle speed of 50 rpm.
  • Example 1 to 5 The results showed that the particles prepared in Examples 1 to 5 were prepared by using 20 wt% ethanol, 50 wt% ethanol, 80 wt% ethanol aqueous solution, 93.75 wt% ethanol and absolute ethanol as a wetting agent, and the particle size distribution was ideal, and the dissolution of the compound A was rapid. complete.
  • the ratio of the dissolution of Compound A was not good in the tablets prepared in the same manner as in Example 1 using purified water as a wetting agent.
  • a wetting agent containing ethanol was used, and in the prepared tablets, the dissolution uniformity of the compound A was good.
  • the dissolution rates of the tablets of Examples 6 to 11 were measured according to the second method (paddle method) of the dissolution test of the Appendix 2 of the Chinese Pharmacopoeia. 900 ml of a 0.1 mol/L hydrochloric acid solution was used as a dissolution medium, and a dissolution test was performed at 37 ⁇ 0.5 ° C at a paddle speed of 50 rpm. The results showed that in the tablets of Examples 6 to 9 containing different proportions of disintegrant in the formulation and the tablets of Examples 10 and 11 containing the compound A in different proportions in the formulation, the dissolution of Compound A was quickly completed.
  • the dissolution profile is shown in Figure 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种含有喹啉衍生物或其盐的药物组合物的制备方法。具体而言，本发明提供了一种含有(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺或其药理学上可接受的盐的药物组合物的制备方法，包括在本发明所述的药物组合物的制备过程中，使用含有至少一种有机溶剂的润湿剂进行湿法制粒。采用本发明所述方法制备的药物组合物具有制备过程中的颗粒分布均匀，组合物溶出迅速而且均一的特点。

Description

一种含有喹啉衍生物或其盐的药物组合物的制备方法 技术领域
本发明属于药物制剂领域，具体涉及一种药物组合物的制备方法，所述组合物含有化学名为(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺的活性药物或其药理学上可接受的盐及至少一种药学上可接受的赋形剂，在本发明所述的药物组合物的制备过程中，使用含有至少一种有机溶剂的润湿剂进行湿法制粒。采用本发明所述方法制备的药物组合物具有制备过程中的颗粒分布均匀，组合物溶出迅速而且均一的特点。。
背景技术
CN102471312B公开了一种小分子化合物(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺，该化合物具有式I所示的结构，
Figure PCTCN2017072156-appb-000001
已知其为小分子受体酪氨酸激酶抑制剂，抑制表皮生长因子受体(EGFR)和人表皮因子受体2(ERBB2)。其可以与细胞内EGFR和ERBB2的激酶区的ATP结合位点共价结合，阻止肿瘤细胞内EGFR和ERBB2的同质和异质二聚体形成，抑制其自身的磷酸化，阻断下游信号通路的激活，从而抑制肿瘤细胞生长。临床上可用于胃癌、肺癌、乳腺癌等多种肿瘤的治疗。
CN102933574B公开了式I化合物的马来酸盐形式，其相对于其他盐和式I化合物本身在溶解度以及生物利用度和药代动力学方面更具优势。
CN103974949B公开了式I化合物二马来酸盐的I型结晶。该晶型具有良好的晶型稳定性和化学稳定性，可用于制备治疗与EGFR受体酪氨酸激酶或HER-2受体酪氨酸激酶有关的疾病的药物。
但是，在将(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺或其药学上可接受的盐制备成药物固体组合物时，由于活性成分溶解于水后在局部产生较大的粘性，不利于制成药物制剂，同时也造成了药物溶出度下降且不同个体的药物制剂溶出速度不均一。
发明内容
本发明的目的在于提供一种制备出溶出迅速、均一的药物组合物的方法，并且该药物组合物制备工艺简单，更适合工艺化大生产。
本发明提供了一种药物组合物的制备方法，包括：
将活性药物(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺或其药理学上可接受的盐与润湿剂混合并制粒。
其中药理学上可接受的盐可以是盐酸盐、马来酸盐、氢溴酸盐、对甲苯磺酸盐、甲磺酸盐、硫酸盐或乙磺酸盐，优选马来酸盐，更优选二马来酸盐。基于组合物的总重量，所述活性成分的含量范围可以是基于组合物总重量剂计5％-70％，优选10％-50％，更优选20-40％。
在本发明提供的药物组合物的制备方法中，在制粒过程中，润湿剂最后可通过干燥过程去除。所述润湿剂可包含至少一种有机溶剂，还可包含水，其中有机溶剂可以是低毒性的有机溶剂，优选乙醇、丙酮等，更优选乙醇。基于润湿剂的总重量，所述有机溶剂的含量可以是20～100％，优选50～95％，更优选50～80％。
本发明提供了的药物组合物的制备方法，还包括将制得颗粒干燥，然后压片制成片剂或灌装制成胶囊，获得便于临床给药的口服固体制剂。
在本发明提供的药物组合物的制备方法中，药物组合物中可以含有一种或多种药学上可接受的赋形剂，例如填充剂、崩解剂、粘合剂、润滑剂等。
所述的填充剂可以是微晶纤维素、磷酸氢钙、甘露醇、预胶化淀粉、乳糖等中的一种或多种。基于组合物的总重量，所述填充剂含量为约5-80％。
所述的粘合剂可以是羟丙甲纤维素、羟丙基纤维素、羧甲基纤维素钠、聚乙烯吡咯烷酮、甲基纤维素等中的一种或多种，基于组合物的总重量，所述粘合剂含量为约0.5-15％。
所述的崩解剂可以是低取代羟丙基纤维素、交联羧甲基纤维素钠、羧甲基淀粉钠、交联聚乙烯吡咯烷酮中的一种或多种，其中优选交联聚乙烯吡咯烷酮，崩解剂的含量为基于组合物总重量的2-20％，优选4-15％，更优选6-10％。
所述的润滑剂可以是滑石粉、硬脂酸镁、硬脂酸锌、山嵛酸甘油酯、月桂基硫酸钠、氢化植物油、胶体二氧化硅等中的一种或多种。基于组合物的总重量，润滑剂的含量为约0.5-5％。
在本发明提供的药物组合物的制备方法中，赋形剂中的一种或多种(例如填充剂、崩解剂、粘合剂)可以与润湿剂以及活性成分一起混合后制粒，然后干燥；或者在将仅有活性成分与润湿剂混合制得的颗粒干燥后加入一种或多种赋形剂；也可以将赋形剂的一部分与活性成分以及润湿剂一起混合而另一部分在制粒干燥后加入。优选地，将填充剂、崩解剂以及粘合剂与活性成分以及润湿剂一起混合， 然后制粒干燥，再加入润滑剂。
本发明还提供了一种药物组合物的制备方法，包括：
将活性药物(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺或其药理学上可接受的盐与润湿剂混合，制粒，干燥，压片制成片剂或灌装制成胶囊，其中，所述润湿剂可以是乙醇与水的混合溶剂，所述乙醇的含量可以是基于润湿剂的总重量的50～80％，所述药物组合物还可以包含：
1)2-20wt％的崩解剂，所述崩解剂为交联聚乙烯吡咯烷酮；
2)5-80wt％的填充剂，所述填充剂选自乳糖和微晶纤维素中的一种或多种；
3)0.5-15wt％的粘合剂，所述粘合剂选自聚乙烯吡咯烷酮、羟丙基甲基纤维素及羟丙基纤维素中的一种或多种；
4)0.5-5wt％的润滑剂，所述润滑剂选自硬脂酸镁和滑石粉的一种或多种。
其中，所述各组分的含量百分比均以药物组合物总重量计。
根据本发明提供的药物组合物的制备方法，相较于纯水，包含了乙醇等低毒性有机溶剂的润湿剂在湿法制粒时制备出的颗粒粒径分布更加理想，制成口服固体制剂后，活性药物溶出更加迅速完全而且均一，更有利于药物发挥药效。
通过本发明提供的制备方法制得的药物组合物溶出迅速，起效显著，可用于胃癌、肺癌或乳腺癌等癌症的治疗。
附图说明
图1显示实施例1～5以及比较例1颗粒粒径分情况。
图2显示比较例1多片样品在0.1mol/L盐酸溶液中的溶出曲线。
图3显示实施例1多片样品在0.1mol/L盐酸溶液中的溶出曲线。
图4显示实施例2多片样品在0.1mol/L盐酸溶液中的溶出曲线。
图5显示实施例3多片样品在0.1mol/L盐酸溶液中的溶出曲线。
图6显示实施例4多片样品在0.1mol/L盐酸溶液中的溶出曲线。
图7显示实施例5多片样品在0.1mol/L盐酸溶液中的溶出曲线。
图8显示实施例6～11的片剂在0.1mol/L盐酸溶液中的溶出曲线。
具体实施方式
通过以下实施例和实验例进一步详细说明本发明。这些实施例和实验例仅用于说明性目的，而并不用于限制本发明的范围。
实施例1～5，比较例1
以表1的处方比例，将(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺的马来酸盐(以下简称为化合物A)、乳糖、微晶纤维素、聚乙烯吡咯烷酮、交联聚乙烯吡咯烷酮混合，分别 以适量纯化水、20wt％乙醇的水溶液、50wt％乙醇的水溶液、80wt％乙醇的水溶液、93.75wt％乙醇的水溶液和无水乙醇为润湿剂湿法制粒，干燥至水分小于2％进行干整粒，加入处方量的硬脂酸镁，采用旋转总混机进行混合。将得到的总混颗粒分装100g用于筛分，其余颗粒压片、包衣，制备成片剂。
表1
Figure PCTCN2017072156-appb-000002
单位：质量％
实验例1：筛分实验
选取50目、100目筛网对实施例1～5以及比较例1得到的100g分装颗粒进行震荡筛分。比例较例1用纯化水作为润湿剂，制备的颗粒，大颗粒和细粉均较多，粒径分布不理想，实施例1～5使用含有乙醇的润湿剂，制备的颗粒粒径分布较均一，大颗粒和细粉均较少。
筛分结果见图1。
实验例2：溶出实验
根据中国药典2010版二部附录溶出度测定第二法(桨法)，对实施例1～5和比较例1的片剂进行溶出度测定。使用900ml的0.1mol/L盐酸溶液作为溶出介质，并在37±0.5℃下以50rpm的桨速进行溶出试验。结果表明，实施例1～5用20wt％乙醇、50wt％乙醇、80wt％乙醇的水溶液、93.75wt％乙醇、无水乙醇作为润湿剂，制备的颗粒，粒径分布较理想，化合物A溶出迅速完全。比例较例1用纯化水作为润湿剂，制成的片剂中，化合物A溶出均一性不好。实施例1～5使用含有乙醇的润湿剂，制成的片剂中，化合物A溶出均一性较好。
溶出曲线图见图2～7，图中所示R1～R6为试验样品片1～片6。
实施例6～11
以表2的处方比例，将化合物A、乳糖、微晶纤维素、聚乙烯吡咯烷酮、交 联聚乙烯吡咯烷酮混合，以适量93.75wt％乙醇的水溶液为润湿剂进行湿法制粒，干燥至水分小于2％进行干整粒，加入处方量的硬脂酸镁，采用旋转总混机进行混合。将得到的总混颗粒压片、包衣，制备成片剂。
表2
Figure PCTCN2017072156-appb-000003
单位：质量％
实验例3：溶出实验
根据中国药典2010版二部附录溶出度测定第二法(桨法)，对实施例6～11的片剂进行溶出度测定。使用900ml的0.1mol/L盐酸溶液作为溶出介质，并在37±0.5℃下以50rpm的桨速进行溶出试验。结果表明，处方中含有不同比例崩解剂的实施例6～9的片剂和处方中含有不同比例化合物A的实施例10、11的片剂中，化合物A溶出迅速完全。
溶出曲线图见图8。

Claims (16)

  1. 一种药物组合物的制备方法，包括：将活性药物(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺或其药理学上可接受的盐与润湿剂混合并制粒的步骤。
  2. 根据权利要求1所述的药物组合物的制备方法，其特征在于，还包括将制得颗粒干燥，然后压片制成片剂或灌装制成胶囊的步骤。
  3. 根据权利要求1所述的药物组合物的制备方法，其中所述润湿剂包含至少一种有机溶剂。
  4. 根据权利要求3所述的药物组合物的制备方法，其中所述润湿剂还含有水。
  5. 根据权利要求3所述的药物组合物的制备方法，其中所述润湿剂为至少一种有机溶剂，或有机溶剂与水的混合溶剂。
  6. 根据权利要求3或5所述的药物组合物的制备方法，所述有机溶剂为乙醇或丙酮，优选乙醇。
  7. 根据权利要求3或5所述的药物组合物的制备方法，所述有机溶剂的含量为基于润湿剂总重量计的20-100wt％，优选50-95wt％，更优选50-80wt％。
  8. 根据权利要求1所述的药物组合物的制备方法，其中所述活性药物的含量为基于组合物总重量的5％-70％，优选10％-50％，更优选20-40％。
  9. 根据权利要求1所述的药物组合物的制备方法，其中所述药理学上可接受的盐为马来酸盐，优选二马来酸盐。
  10. 根据权利要求1所述的药物组合物的制备方法，其特征在于所述药物组合物包含填充剂，所述填充剂优选微晶纤维素、磷酸氢钙、甘露醇、预胶化淀粉和乳糖中的一种或多种，优选填充剂的含量为基于组合物总重量计的5-80％。
  11. 根据权利要求1所述的药物组合物的制备方法，其特征在于所述药物组合物包含粘合剂，所述粘合剂优选羟丙甲纤维素、羟丙基纤维素、羧甲基纤维素钠、聚乙烯吡咯烷酮、甲基纤维素中的一种或多种，优选粘合剂的含量为基于组合物总重量计的0.5-15％。
  12. 根据权利要求1所述的药物组合物的制备方法，其特征在于所述药物组合物包含崩解剂，所述崩解剂可选自低取代羟丙基纤维素、交联羧甲基纤维素钠、羧甲基淀粉钠、交联聚乙烯吡咯烷酮中的一种或多种，优选崩解剂的含量为基于组合物总重量的2-20％，优选4-15％，更优选6-10％。
  13. 根据权利要求1所述的药物组合物的制备方法，其特征在于所述药物组合物包含润滑剂，所述润滑剂优选滑石粉、硬脂酸镁、硬脂酸锌、山嵛酸甘油酯、月桂基硫酸钠、氢化植物油、胶体二氧化硅中的一种或多种，优选润滑剂的含量为基于组合物总重量计的0.5-5％。
  14. 一种药物组合物的制备方法，包括如下步骤：
    将活性药物(R,E)-N-(4-(3-氯-4-(吡啶-2-基甲氧基)苯基氨基)-3-氰基-7-乙氧基喹啉-6-基)-3-(1-甲基吡咯烷基-2-基)-丙烯酰胺或其药理学上可接受的盐与润湿剂混合，制粒，干燥，压片制成片剂或灌装制成胶囊，其中，所述润湿剂为乙醇与水的混合溶剂，所述乙醇的含量为基于润湿剂的总重量的50～80％，所述药物组合物还包含：
    1)2-20wt％的崩解剂，所述崩解剂为交联聚乙烯吡咯烷酮；
    2)5-80wt％的填充剂，所述填充剂选自乳糖和微晶纤维素中的一种或多种；
    3)0.5-15wt％的粘合剂，所述粘合剂选自聚乙烯吡咯烷酮、羟丙基甲基纤维素及羟丙基纤维素中的一种或多种；
    4)0.5-5wt％的润滑剂，所述润滑剂选自硬脂酸镁和滑石粉的一种或多种。
  15. 通过权利要求1到14任一项所述的制备方法得到的药物组合物。
  16. 权利要求15所述的药物组合物在制备治疗癌症的药物中的用途；所述癌症优选胃癌、肺癌或乳腺癌。
PCT/CN2017/072156 2016-01-27 2017-01-23 一种含有喹啉衍生物或其盐的药物组合物的制备方法 WO2017129088A1 (zh)

Priority Applications (19)

Application Number Priority Date Filing Date Title
RU2018128416A RU2735807C2 (ru) 2016-01-27 2017-01-23 Способ получения фармацевтической композиции, включающей производное хинолина или его соль
PL17743703T PL3378479T3 (pl) 2016-01-27 2017-01-23 Sposób przygotowania kompozycji farmaceutycznej zawierającej pochodną chinoliny lub jej sól
BR112018014544-0A BR112018014544A2 (zh) 2016-01-27 2017-01-23 A process for the preparation of a pharmaceutical composition comprising a quinoline derivative or a salt thereof
SI201730345T SI3378479T1 (sl) 2016-01-27 2017-01-23 Postopek za pripravo farmacevtskega sestavka, ki obsega derivat kinolina ali njegovo sol
EP17743703.5A EP3378479B1 (en) 2016-01-27 2017-01-23 Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
CN201780000924.3A CN107405345A (zh) 2016-01-27 2017-01-23 一种含有喹啉衍生物或其盐的药物组合物的制备方法
RS20200902A RS60747B1 (sr) 2016-01-27 2017-01-23 Postupak za dobijanje farmaceutske supstance koja obuhvata derivat hinolina ili njegovu so
JP2018534780A JP6937308B2 (ja) 2016-01-27 2017-01-23 キノリン誘導体またはその塩を含有する医薬組成物の製造方法
AU2017211737A AU2017211737B2 (en) 2016-01-27 2017-01-23 Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
US16/071,572 US10722469B2 (en) 2016-01-27 2017-01-23 Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
CA3008701A CA3008701A1 (en) 2016-01-27 2017-01-23 Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
ES17743703T ES2811031T3 (es) 2016-01-27 2017-01-23 Procedimiento para la preparación de una composición farmacéutica que comprende un derivado de quinolina o una sal del mismo
MX2018008862A MX2018008862A (es) 2016-01-27 2017-01-23 Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo.
DK17743703.5T DK3378479T3 (da) 2016-01-27 2017-01-23 Fremgangsmåde til forberedelse af farmakologisk sammensætning, der omfatter qionolinderivat eller salt deraf
KR1020187022626A KR20180103090A (ko) 2016-01-27 2017-01-23 퀴놀린 유도체 또는 그의 염을 포함하는 약학적 조성물의 제조 방법
LTEP17743703.5T LT3378479T (lt) 2016-01-27 2017-01-23 Farmacinės kompozicijos, apimančios chinolino darinį arba jo druską, paruošimo būdas
HK18103053.8A HK1243357A1 (zh) 2016-01-27 2018-03-02 一種含有喹啉衍生物或其鹽的藥物組合物的製備方法
HRP20201155TT HRP20201155T1 (hr) 2016-01-27 2020-07-23 Postupak dobivanja farmaceutskog pripravka koji sadrži derivat kinolina ili njegovu sol
CY20201100686T CY1123149T1 (el) 2016-01-27 2020-07-27 Μεθοδος για την παρασκευη φαρμακευτικης συνθεσης που περιλαμβανει παραγωγο κινολινης ή αλας αυτου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610057228.3 2016-01-27
CN201610057228 2016-01-27

Publications (1)

Publication Number Publication Date
WO2017129088A1 true WO2017129088A1 (zh) 2017-08-03

Family

ID=59397365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/072156 WO2017129088A1 (zh) 2016-01-27 2017-01-23 一种含有喹啉衍生物或其盐的药物组合物的制备方法

Country Status (23)

Country Link
US (1) US10722469B2 (zh)
EP (1) EP3378479B1 (zh)
JP (1) JP6937308B2 (zh)
KR (1) KR20180103090A (zh)
CN (2) CN107405345A (zh)
AU (1) AU2017211737B2 (zh)
BR (1) BR112018014544A2 (zh)
CA (1) CA3008701A1 (zh)
CY (1) CY1123149T1 (zh)
DK (1) DK3378479T3 (zh)
ES (1) ES2811031T3 (zh)
HK (1) HK1243357A1 (zh)
HR (1) HRP20201155T1 (zh)
HU (1) HUE050255T2 (zh)
LT (1) LT3378479T (zh)
MX (1) MX2018008862A (zh)
PL (1) PL3378479T3 (zh)
PT (1) PT3378479T (zh)
RS (1) RS60747B1 (zh)
RU (1) RU2735807C2 (zh)
SI (1) SI3378479T1 (zh)
TW (1) TWI720115B (zh)
WO (1) WO2017129088A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109496150A (zh) * 2018-03-23 2019-03-19 无锡双良生物科技有限公司 一种药物组合物及其制备方法和用途
WO2019080830A1 (zh) 2017-10-24 2019-05-02 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物的药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN102471312B (zh) 2009-09-14 2014-06-18 江苏恒瑞医药股份有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN103974949B (zh) 2012-07-12 2015-11-25 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515212A (ja) * 2001-12-21 2005-05-26 ファイザー・プロダクツ・インク アジスロマイシンの湿式造粒法
WO2004032905A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
US20130150386A1 (en) * 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
CN103987700B (zh) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-喹唑啉胺类衍生物及其用途
AU2016211246B2 (en) * 2015-01-30 2020-08-27 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22CI2N4O2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102471312B (zh) 2009-09-14 2014-06-18 江苏恒瑞医药股份有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN102933574B (zh) 2011-03-11 2014-10-01 上海恒瑞医药有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN103974949B (zh) 2012-07-12 2015-11-25 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019080830A1 (zh) 2017-10-24 2019-05-02 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物的药物组合物
CN110769825A (zh) * 2017-10-24 2020-02-07 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物的药物组合物
JP2021500363A (ja) * 2017-10-24 2021-01-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． キノリン誘導体を含む医薬組成物
EP3701948A4 (en) * 2017-10-24 2021-08-25 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION WITH QUINOLINE DERIVATIVE
CN110769825B (zh) * 2017-10-24 2022-06-21 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物的药物组合物
US11701349B2 (en) 2017-10-24 2023-07-18 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing quinoline derivative
CN109496150A (zh) * 2018-03-23 2019-03-19 无锡双良生物科技有限公司 一种药物组合物及其制备方法和用途
US11786527B2 (en) 2018-03-23 2023-10-17 Wuxi Shuangliang Biotechnology Co., Ltd. Pharmaceutical composition and preparation method therefor and uses thereof

Also Published As

Publication number Publication date
CN108938586B (zh) 2021-05-14
HUE050255T2 (hu) 2020-11-30
ES2811031T3 (es) 2021-03-10
JP6937308B2 (ja) 2021-09-22
PL3378479T3 (pl) 2020-11-02
EP3378479A4 (en) 2018-12-19
PT3378479T (pt) 2020-07-20
RS60747B1 (sr) 2020-10-30
SI3378479T1 (sl) 2020-10-30
AU2017211737B2 (en) 2022-04-28
CY1123149T1 (el) 2021-10-29
DK3378479T3 (da) 2020-08-03
EP3378479A1 (en) 2018-09-26
EP3378479B1 (en) 2020-06-17
US10722469B2 (en) 2020-07-28
RU2735807C2 (ru) 2020-11-09
CA3008701A1 (en) 2017-08-03
HRP20201155T1 (hr) 2020-10-30
US20190054025A1 (en) 2019-02-21
CN107405345A (zh) 2017-11-28
RU2018128416A (ru) 2020-02-27
LT3378479T (lt) 2020-09-10
BR112018014544A2 (zh) 2018-12-11
MX2018008862A (es) 2018-09-07
TWI720115B (zh) 2021-03-01
KR20180103090A (ko) 2018-09-18
TW201726138A (zh) 2017-08-01
AU2017211737A1 (en) 2018-08-02
RU2018128416A3 (zh) 2020-04-21
CN108938586A (zh) 2018-12-07
HK1243357A1 (zh) 2018-07-13
JP2019503373A (ja) 2019-02-07

Similar Documents

Publication Publication Date Title
JP6577143B2 (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
WO2017028660A1 (zh) 一种含有喹啉衍生物或其盐的药物组合物
BR112014032764B1 (pt) Composição farmacêutica contendo fimasartana e hidroclorotiazida, método para preparação de uma composição farmacêutica e uso de fimasartana e hidroclorotiazida
BR112020026493A2 (pt) Formulações de ag10
US20140341993A1 (en) Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method of production thereof
WO2017129088A1 (zh) 一种含有喹啉衍生物或其盐的药物组合物的制备方法
KR102294190B1 (ko) 신규한 용출 파라미터를 이용한 모사프리드 함유 서방제제
TWI726978B (zh) 一種含有喹啉衍生物或其鹽的藥物組成物
KR102720987B1 (ko) 퀴놀린 유도체 또는 그의 염을 포함하는 약학적 조성물
JPWO2019230937A1 (ja) 溶出性に優れた経口固形製剤
TW202112376A (zh) 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
CN113491695A (zh) 一种仑伐替尼药物组合物、其制备方法及应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17743703

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3008701

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2017743703

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018534780

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017743703

Country of ref document: EP

Effective date: 20180621

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/008862

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018014544

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 12018501579

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017211737

Country of ref document: AU

Date of ref document: 20170123

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20187022626

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020187022626

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 112018014544

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180717